Turn Therapeutics Inc. (TTRX) research

Turn Therapeutics Inc.

Sector: Healthcare
Industry: Biotechnology
Last price: $13.33
As of: 2026-10-02

Turn Therapeutics Inc. (TTRX): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-10.

As of 2026-09-10, the latest of: this ticker's 13F holdings load, its latest SEC filing date, and its latest signal other than 13F-derived signals. Source: SEC EDGAR filings for TTRX. Method and limitations.

COMPANY DOSSIER

See the full TTRX dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for TTRX on one page. Preview it with sample data, then open it live with a free account.

Preview the TTRX dossier

Active signals for TTRX

lowEARNINGS_BEAT2026-06-17
Q4-2025: EPS $0.01 vs $-0.0408 estimate, +0.05 on a near-zero consensus
All 2026-06-17 signals →

FREE, NO ACCOUNT

Every signal on TTRX, as it fires

New filings, 13F moves and cross asset signals on TTRX land in the record first.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in TTRX (2026Q2)

Manager / security	Market value	% portfolio	QoQ
MILLENNIUM MANAGEMENT LLCCUSIP 90021W105 · 2026Q2	$442K	0.00%	,
CITADEL ADVISORS LLCCUSIP 90021W105 · 2026Q2	$189K	0.00%	,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, TTRX

8-K2026-09-10
SEC EDGAR ↗
8-K2026-09-09
SEC EDGAR ↗
8-K2026-08-18
SEC EDGAR ↗
8-K2026-08-17
SEC EDGAR ↗
8-K2026-08-12
SEC EDGAR ↗
10-Q2026-08-12
SEC EDGAR ↗
8-K2026-07-28
SEC EDGAR ↗
8-K2026-07-07
SEC EDGAR ↗
8-K2026-06-03
SEC EDGAR ↗
8-K2026-06-01
SEC EDGAR ↗

TTRX against its peers

TTRX's return on equity of -68.2% ranks in the 58th percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.

Metric	TTRX	Peer median	Percentile	n
Revenue FY	n/a	40.5M	n/a	13
Operating margin	n/a	-212.9%	n/a	13
Net margin	n/a	-203.3%	n/a	13
Return on equity	-68.2%	-77.1%	58	17

Peers (21): GALT, ZURA, RLMD, EDIT, RZLT, CCCC, SPRY, KYTX, MYGN, IRD, ENTA, ARCT, AGEN, INDP, FENC, PRTA, OBIO, TECX, PROK, DMAC, SRZN. Left out: SCTX (no annual filing), EIKN (no annual filing), PRTC (period gap), AGMB (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (TTRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more TTRX signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to TTRXand get the insider, 13F, options, and confluence read in one view.